Interference with the signaling capacity of CC chemokine receptor 5 can compromise its role as an HIV-1 entry coreceptor in primary T lymphocytes.
Wang
J M
JM
Laboratory of Molecular Immunoregulation, Division of Basic Sciences, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland 21702-1201, USA. wangji@mail.ncifcrf.gov
Oppenheim
J J
JJ
D065100:CCR5 Receptor Antagonists; D002118:Calcium / Q000378:metabolism; D002478:Cells, Cultured; D015686:Gene Products, env / Q000502:physiology; D015497:HIV-1 / Q000187:drug effects / Q000472:pathogenicity / Q000502:physiology*; D006801:Humans; D008561:Membrane Fusion / Q000502:physiology; D008954:Models, Biological; D019713:Receptors, CCR5 / Q000187:drug effects / Q000502:physiology*; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000187:drug effects / Q000502:physiology / Q000821:virology*; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D065100:CCR5 Receptor Antagonists; D015686:Gene Products, env; D019713:Receptors, CCR5; D010566:Virulence Factors, Bordetella; D002118:Calcium